京新药业(002020) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥956,068,676.24, a decrease of 9.86% compared to ¥1,060,660,180.25 in the same period last year[4] - Net profit attributable to shareholders was ¥163,292,650.63, down 4.62% from ¥171,207,841.45 year-on-year[4] - Total operating revenue decreased to ¥956,068,676.24 from ¥1,060,660,180.25, representing a decline of approximately 9.8% year-over-year[19] - Net profit for the period was ¥165,381,300.92, down from ¥173,212,132.61, reflecting a decrease of approximately 4.8%[19] - The weighted average return on net assets decreased by 0.29 percentage points to 2.77% from 3.06% year-on-year[4] - Research and development expenses were ¥87,331,667.77, down from ¥98,380,244.05, a decrease of approximately 11.2%[19] Cash Flow - The net cash flow from operating activities decreased by 53.92%, amounting to ¥162,892,743.70 compared to ¥353,529,027.32 in the previous year[8] - The company reported a net cash flow from operating activities of ¥162,892,743.70, down from ¥353,529,027.32, indicating a decline of about 53.9%[21] - The net cash flow from financing activities was -$538,954,381.34, a decline from a positive$48,665,662.75 in the previous period, indicating challenges in financing[22] - The net increase in cash and cash equivalents was $94,416,109.55, compared to$698,822,014.51 previously, indicating a decrease in liquidity growth[22] - The ending balance of cash and cash equivalents was $381,561,042.25, down from$1,974,840,382.26, reflecting a significant reduction in cash reserves[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,986,569,416.25, a decline of 5.81% from ¥8,479,313,218.60 at the end of the previous year[4] - The company’s non-current assets decreased to ¥5.27 billion from ¥5.57 billion, a reduction of approximately 5.2%[16] - The total liabilities decreased to ¥2,262,918,112.21 from ¥2,477,769,425.69, a reduction of approximately 8.7%[17] - Total equity attributable to shareholders decreased to ¥5,689,530,119.19 from ¥5,969,508,653.97, reflecting a decline of about 4.7%[17] - The company’s total liabilities decreased, with short-term borrowings reduced to RMB 190 million from RMB 281.36 million, a decrease of about 32.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,705, with no preferred shareholders[9] - The largest shareholder, Lü Gang, holds 20.77% of the shares, amounting to 178,796,755 shares[9] Investment Activities - The company reported a significant increase in investment income, which rose by 145.73% to ¥4,406,931.90 from ¥1,793,438.35 in the previous year[7] - The company experienced a 911.56% increase in current non-current assets, totaling ¥348,427,624.42, primarily due to an increase in time deposits[7] - The net cash flow from investment activities was $470,473,743.64, an increase from$295,293,598.31 in the previous period, indicating strong investment performance[22] - Total cash inflow from investment activities amounted to $1,097,601,857.61, compared to$482,772,965.94 previously, reflecting a significant growth[22] - Cash outflow for investment activities was $627,128,113.97, up from$187,479,367.63, showing increased investment spending[22] Share Repurchase - The company plans to repurchase shares with a total amount not less than RMB 350 million and not exceeding RMB 400 million, with a maximum repurchase price of RMB 14.8 per share, potentially acquiring approximately 13.51 million to 27.03 million shares, representing about 1.57% to 3.14% of the total share capital[11] - As of March 31, 2025, the company has repurchased 35,099,975 shares, accounting for 4.08% of the total share capital, with a total transaction amount of RMB 443.18 million[12] - The company has adjusted the total repurchase fund amount to not less than RMB 350 million and not exceeding RMB 700 million, maintaining the other terms of the repurchase plan unchanged[12] Other Information - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[23] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[24]